Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of TAK-360 in Central Hypersomnia Disorders
jRCT2031260198Recruiting
- Sponsor
- Takeda
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of TAK-360 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and hypersomnolence disorder (3 arms), sponsored by Takeda. Primary endpoint: Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE). Started Jun 2026; status: recruiting.
02
Drugs
TAK-360
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on jRCT2031260198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260198.